Tuesday, May 16, 2017

Forge Therapeutics Names Board

San Diego-based antibiotics developer Forge Therapeutics announced oday that it has named its board of directors, adding Mario Polywka (COO of Evotec AG), John Schmid, (former CFO of Trius and Auspex Pharmaceuticals), Stephen Worland (President and CEO of eFFECTOR Therapeutics), Brian T. Dorsey (MagnaSci Ventures), and Zachary Zimmerman (CEO of Forge), with Jonathan Kabakoff (Alexandria Venture Investments) and Jeffrey Moore (MP Healthcare Venture Management) serving as observers. Forge Therapeutics recently raised $15M in a Series A, from MagnaSci Ventures, Evotec AG, Alexandria Venture Investments, MP Healthcare Venture Management, Red Apple Group, and WS Investments.